RELIEF THERAPEUTICS S/ADR (RLFTY)
RLFTY moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How RLFTY actually reacts to news — the realized, point-in-time move the market made, measured across 40 labeled events over the last three years with zero look-ahead.
RLFTY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 13% | 24 |
| 30-min | 0.00% | 21% | 24 |
| 60-min | 0.00% | 21% | 24 |
| to close | 0.00% | 26% | 23 |
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when RLFTY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RLFTY's baseline. Nothing else.
Recent RLFTY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank | Press release | ACCESS Newswire | — | — | |
| MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics | Press release | ACCESS Newswire | — | — | |
| Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics | Press release | ACCESS Newswire | -2.50% | -46.43% | |
| Relief Therapeutics Shareholders Approve Business Combination with NeuroX | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 | Press release | ACCESS Newswire | — | — | |
| Relief Therapeutics Publishes 2025 Half-Year Report | Press release | ACCESS Newswire | — | — | |
| Relief Therapeutics Advances Publication of 2025 Half-Year Report | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze | Press release | ACCESS Newswire | +0.00% | — | |
| Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Relief Therapeutics Announces Results of Annual General Meeting | Press release | ACCESS Newswire | +0.00% | -1.35% | |
| Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 | Press release | ACCESS Newswire | +0.00% | -7.62% | |
| Relief Therapeutics Publishes 2025 Annual General Meeting Agenda | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion | Press release | ACCESS Newswire | — | — | |
| Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 | Press release | ACCESS Newswire | +0.00% | +5.62% | |
| Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US | Press release | Accesswire | +1.21% | +1.21% | |
| Relief Therapeutics Provides Update on Potential Transaction with Renexxion | Press release | Accesswire | +0.00% | +5.59% | |
| Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial | Press release | Accesswire | +0.00% | -8.37% | |
| Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations | Press release | Accesswire | +0.00% | -8.37% | |
| Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | Press release | Accesswire | +0.00% | +4.25% | |
| Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger | Press release | Accesswire | +2.13% | +7.09% | |
| Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE | Press release | Accesswire | +0.00% | +0.00% | |
| Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents | Press release | Accesswire | +0.00% | -4.10% | |
| Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment | Press release | Accesswire | +0.00% | -9.02% | |
| Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | Press release | Accesswire | +5.00% | +16.19% | |
| Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria | Press release | Accesswire | +0.00% | +0.00% | |
| Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement | Press release | Accesswire | +0.00% | +0.00% | |
| Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 | Press release | Accesswire | — | — | |
| Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 | Press release | Accesswire | +0.00% | -11.89% | |
| Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update | Press release | Accesswire | — | — | |
| Relief Therapeutics Secures up to $11 Million from Royalty Sales | Press release | Accesswire | — | — | |
| RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting | Press release | Accesswire | — | — | |
| Relief Therapeutics Announces Executive Changes | Press release | Accesswire | — | — | |
| Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders | Press release | Accesswire | — | — | |
| Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives | Press release | Accesswire | +0.00% | +0.00% | |
| Relief Therapeutics has Published its Annual Report | Press release | Accesswire | — | — | |
| RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting | Press release | Accesswire | — | — | |
| RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting | Press release | Accesswire | — | — | |
| Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE | Press release | Accesswire | — | — | |
| Relief Therapeutics Announces CEO Transition | Press release | Accesswire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RLFTY section they belong to.
Where else RLFTY is measured.
RLFTY earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is RELIEF THERAPEUTICS S/ADR's median reaction calculated?
Every labeled RLFTY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 40 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 21% of RLFTY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RLFTY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.